| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advisory Group recommendations on priorities for the IARC Monographs
|
|
|
2019
|
20 |
6 |
p. 763-764
|
artikel
|
| 2 |
A new player in the treatment of HER2-positive tumours
|
Giannone, Gaia
|
|
2019
|
20 |
6 |
p. 748-750
|
artikel
|
| 3 |
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
|
Eng, Cathy
|
|
2019
|
20 |
6 |
p. 849-861
|
artikel
|
| 4 |
A white disease—the experience of cancer for black and ethnic minority women
|
Lucas, Catherine
|
|
2019
|
20 |
6 |
p. 768
|
artikel
|
| 5 |
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
|
Wilky, Breelyn A
|
|
2019
|
20 |
6 |
p. 837-848
|
artikel
|
| 6 |
Breast cancer screening by visually impaired women
|
Varatharajah, Ryan
|
|
2019
|
20 |
6 |
p. e299
|
artikel
|
| 7 |
Cancer hospital advertising and outcomes: trust the messenger?
|
Lipitz-Snyderman, Allison
|
|
2019
|
20 |
6 |
p. 760-762
|
artikel
|
| 8 |
CAR T-cell therapy for relapsed or refractory multiple myeloma
|
Stirrups, Robert
|
|
2019
|
20 |
6 |
p. e297
|
artikel
|
| 9 |
Clinical trial registry reporting: a transparent solution needed
|
The Lancet Oncology,
|
|
2019
|
20 |
6 |
p. 741
|
artikel
|
| 10 |
Correction to Lancet Oncol 2016; 17: 747–56
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 827–36
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 816–26
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 13 |
Correction to Lancet Oncol 2019; 20: 297–310
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 14 |
Correction to Lancet Oncol 2019; 20: 849–61
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 15 |
Correction to Lancet Oncol 2017; 18: 1061–75
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 16 |
Correction to Lancet Oncol 2018; 19: 1530–42
|
|
|
2019
|
20 |
6 |
p. e293
|
artikel
|
| 17 |
Correction to Lancet Oncol 2019; 20: e262–73
|
|
|
2019
|
20 |
6 |
p. 293
|
artikel
|
| 18 |
Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study
|
Wilson, Brooke E
|
|
2019
|
20 |
6 |
p. 769-780
|
artikel
|
| 19 |
Genetic risk classifier to predict localised renal cell carcinoma recurrence
|
Liu, Shufang
|
|
2019
|
20 |
6 |
p. e287
|
artikel
|
| 20 |
Genetic risk classifier to predict localised renal cell carcinoma recurrence – Authors' reply
|
Zhang, Jia-Xing
|
|
2019
|
20 |
6 |
p. e288
|
artikel
|
| 21 |
Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer
|
Wander, Seth A
|
|
2019
|
20 |
6 |
p. 746-748
|
artikel
|
| 22 |
Global chemotherapy demands: a prelude to equal access
|
Arnold, Melina
|
|
2019
|
20 |
6 |
p. 742-743
|
artikel
|
| 23 |
Hepatic arterial chemotherapy for hepatocellular carcinoma
|
Burki, Talha Khan
|
|
2019
|
20 |
6 |
p. e301
|
artikel
|
| 24 |
Idelalisib and rituximab for chronic lymphocytic leukaemia
|
Stirrups, Robert
|
|
2019
|
20 |
6 |
p. e294
|
artikel
|
| 25 |
India's new health scheme: what does it mean for cancer care?
|
Caduff, Carlo
|
|
2019
|
20 |
6 |
p. 757-758
|
artikel
|
| 26 |
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|
Hillengass, Jens
|
|
2019
|
20 |
6 |
p. e302-e312
|
artikel
|
| 27 |
Key considerations when reviewing subsequent primary cancers following radiotherapy
|
Kishan, Amar U
|
|
2019
|
20 |
6 |
p. e291
|
artikel
|
| 28 |
Key considerations when reviewing subsequent primary cancers following radiotherapy – Authors' reply
|
Mohamad, Osama
|
|
2019
|
20 |
6 |
p. e292
|
artikel
|
| 29 |
Mapping a route to Indigenous engagement in cancer genomic research
|
Henare, Kimiora L
|
|
2019
|
20 |
6 |
p. e327-e335
|
artikel
|
| 30 |
Master protocols in clinical trials: a universal Swiss Army knife?
|
Sudhop, Thomas
|
|
2019
|
20 |
6 |
p. e336-e342
|
artikel
|
| 31 |
MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan
|
Sclafani, Francesco
|
|
2019
|
20 |
6 |
p. 752-753
|
artikel
|
| 32 |
Meningeal melanocytosis: a challenging diagnosis
|
Noronha, Carolina
|
|
2019
|
20 |
6 |
p. e343
|
artikel
|
| 33 |
Multidisciplinary care in tenosynovial giant cell tumours
|
Tap, William D
|
|
2019
|
20 |
6 |
p. 755-756
|
artikel
|
| 34 |
New treatment for relapsed or refractory Hodgkin's lymphoma
|
Gourd, Elizabeth
|
|
2019
|
20 |
6 |
p. e298
|
artikel
|
| 35 |
Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review
|
Budach, Volker
|
|
2019
|
20 |
6 |
p. e313-e326
|
artikel
|
| 36 |
Ovarian cancer: time to move beyond one size fits all
|
Secord, Angeles Alvarez
|
|
2019
|
20 |
6 |
p. 754-755
|
artikel
|
| 37 |
Performance of BCRAT in high-risk patients with breast cancer
|
Gail, Mitchell H
|
|
2019
|
20 |
6 |
p. e285
|
artikel
|
| 38 |
Performance of BCRAT in high-risk patients with breast cancer – Authors' reply
|
Terry, Mary Beth
|
|
2019
|
20 |
6 |
p. e286
|
artikel
|
| 39 |
Personalised management of alveolar soft part sarcoma: a promising phase 2 study
|
Penel, Nicolas
|
|
2019
|
20 |
6 |
p. 750-752
|
artikel
|
| 40 |
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|
Richardson, Paul G
|
|
2019
|
20 |
6 |
p. 781-794
|
artikel
|
| 41 |
Promising results with tagraxofusp in BPDCN
|
Gourd, Elizabeth
|
|
2019
|
20 |
6 |
p. e295
|
artikel
|
| 42 |
Redefining the treatment paradigm for multiple myeloma
|
Gay, Francesca
|
|
2019
|
20 |
6 |
p. 743-744
|
artikel
|
| 43 |
Should we stop investing in chemoprevention trials in oncology?
|
Weller, David
|
|
2019
|
20 |
6 |
p. 766-767
|
artikel
|
| 44 |
Single-fraction radiotherapy for bone metastases
|
Das, Manjulika
|
|
2019
|
20 |
6 |
p. e296
|
artikel
|
| 45 |
Social networks for young patients with cancer: the time for system agility
|
Ben-Aharon, Irit
|
|
2019
|
20 |
6 |
p. 765
|
artikel
|
| 46 |
Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study
|
Mastboom, Monique J L
|
|
2019
|
20 |
6 |
p. 877-886
|
artikel
|
| 47 |
The liquid biopsy: towards standardisation in preparation for prime time
|
Page, Karen
|
|
2019
|
20 |
6 |
p. 758-760
|
artikel
|
| 48 |
Tomosynthesis in breast screening: great expectations?
|
Zackrisson, Sophia
|
|
2019
|
20 |
6 |
p. 745-746
|
artikel
|
| 49 |
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
|
Tamura, Kenji
|
|
2019
|
20 |
6 |
p. 816-826
|
artikel
|
| 50 |
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
|
Shitara, Kohei
|
|
2019
|
20 |
6 |
p. 827-836
|
artikel
|
| 51 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
|
Vergote, Ignace
|
|
2019
|
20 |
6 |
p. 862-876
|
artikel
|
| 52 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Jiang, Zefei
|
|
2019
|
20 |
6 |
p. 806-815
|
artikel
|
| 53 |
Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial
|
Hofvind, Solveig
|
|
2019
|
20 |
6 |
p. 795-805
|
artikel
|
| 54 |
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution
|
Palmieri, Carlo
|
|
2019
|
20 |
6 |
p. e289
|
artikel
|
| 55 |
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution – Authors' reply
|
Krens, Stefanie D
|
|
2019
|
20 |
6 |
p. e290
|
artikel
|
| 56 |
Using blockchain technology to recycle cancer drugs
|
Benniche, Saffya
|
|
2019
|
20 |
6 |
p. e300
|
artikel
|
Tijdschrift beschrijving